IMMX vs. LABP, BCAB, RAPT, XBIT, STTK, GTHX, MCRB, ABOS, VTYX, and OTLK
Should you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Landos Biopharma (LABP), BioAtla (BCAB), RAPT Therapeutics (RAPT), XBiotech (XBIT), Shattuck Labs (STTK), G1 Therapeutics (GTHX), Seres Therapeutics (MCRB), Acumen Pharmaceuticals (ABOS), Ventyx Biosciences (VTYX), and Outlook Therapeutics (OTLK). These companies are all part of the "medical" sector.
Landos Biopharma (NASDAQ:LABP) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends.
In the previous week, Immix Biopharma had 5 more articles in the media than Landos Biopharma. MarketBeat recorded 5 mentions for Immix Biopharma and 0 mentions for Landos Biopharma. Landos Biopharma's average media sentiment score of 0.49 beat Immix Biopharma's score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the news media.
Immix Biopharma has lower revenue, but higher earnings than Landos Biopharma. Landos Biopharma is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.
Landos Biopharma presently has a consensus target price of $20.42, indicating a potential downside of 10.95%. Immix Biopharma has a consensus target price of $10.50, indicating a potential upside of 368.75%. Given Landos Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Landos Biopharma.
Landos Biopharma received 23 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 62.50% of users gave Landos Biopharma an outperform vote.
49.1% of Landos Biopharma shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 1.3% of Landos Biopharma shares are owned by company insiders. Comparatively, 55.9% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Immix Biopharma's return on equity of -73.00% beat Landos Biopharma's return on equity.
Landos Biopharma has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.
Summary
Immix Biopharma beats Landos Biopharma on 11 of the 16 factors compared between the two stocks.
Get Immix Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immix Biopharma Competitors List
Related Companies and Tools
Free IMMX Stock Alerts